FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET ANALYSIS

Focal Segmental Glomerulosclerosis Market by Disease Type (Primary Focal Segmental Glomerulosclerosis, and Secondary Focal Segmental Glomerulosclerosis), by Drug (Sparsentan (Phase III)), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Jan 2025
Code : CMI2224
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

The key players operating in the focal segmental glomerulosclerosis (FSGS) market include GlaxoSmithKline plc., Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.